Comment on: Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis

Rheumatology

Volumn 50, Issue 5, 2011, Pages 994-996

  Nagashima, Takao ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOCORTICOID; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; STROMELYSIN;

ADULT; AGED; ANTIBODY DETECTION; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DOSE RESPONSE; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SCLERODERMA, SYSTEMIC;

EID: 79955159395     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker117     Document Type: Letter

References (9)

1. Ueda-Hayakawa I, Hasegawa M, Kumada S et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology 2010;49: 2135-9.
2. Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K. Serum matrix metalloproteinase-3 in systemic sclerosis. Arch Dermatol Res 2004;296:25-9.
3. Ribbens C, Martin y Porras M, Franchimont N et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
4. Yamanaka H, Matsuda Y, Tanaka M et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.
5. Kotajima L, Aotsuka S, Fujimani M et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol 1998;16: 409-15.
6. Matsuyama A, Sakai N, Ishigami M et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 2003;108:1469-73.
7. Keyszer G, Lambiri I, Nagel R et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26: 251-8.
8. Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998;41: 1203-9.
9. Shinozaki M, Inoue E, Nakajima A et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007;17:403-8.